Blocking MHC-I and inhibitory KIR (inhibitory Ly49 murine homologue) restores ADCC and enhances the antitumoral activity of therapeutic mAbs, both ex vivo in humans and in vitro/in vivo in a murine T-cell lymphoma model, resulting in reduced tumor volumes and significantly increased survival rates. Here, KLRA1P is linked to T-cell non-Hodgkin lymphoma.